The co-founders of startup Ricursive Intelligence seemed destined to be co-founders. Anna Goldie, CEO, and Azalia Mirhoseini, CTO, are so well-known in the AI community that they were among those AI ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Abstract: Heterogeneous device-edge-cloud computing infrastructures have become the backbone of modern telecommunication operators and Wide Area Networks (WANs), providing multi-tier computational ...

While the bears dominated price action early last week, the bulls managed to show strong support below $100,000. Bitcoin price dropped briefly below $100,000 on Tuesday, Wednesday, and Friday, but ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Amidst the AI boom transforming various sectors, Recursion Pharmaceuticals (NASDAQ: RXRX), a previously beaten-down AI-biotech, is showing signs of a rebound. Its stock has skyrocketed 25% in the past ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat ...

Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...

Abstract: Current synthetic aperture radar (SAR) missions with short repeat times bring the opportunity to get large-scale deformations in near real-time. Since nonstationary deformation is more ...